Prof. Behrens highlighted the following key takeaways on the impact of skin disease in patients with SpA. To dive deeper, play his bitesize 2-minute interview above!

Prof. Behrens believes that for patients living with PsA, targeting remission of musculoskeletal disease alone is not sufficient; quality of life is also determined by skin disease. For instance, patients who achieve DAPSA-LDA and have active psoriasis still experience a significant quality of life burden owing to skin disease.¹

Rheumatologists and dermatologists must work together to make remission of skin disease in patients with SpA possible.